IQ EQ FUND MANAGEMENT IRELAND Ltd Cuts Position in IDEXX Laboratories, Inc. $IDXX

IQ EQ FUND MANAGEMENT IRELAND Ltd lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 59.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,381 shares of the company’s stock after selling 1,995 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in IDEXX Laboratories were worth $882,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of IDXX. STF Management LP grew its stake in IDEXX Laboratories by 1.3% during the second quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after buying an additional 16 shares during the period. Clearstead Trust LLC boosted its position in IDEXX Laboratories by 1.1% during the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after purchasing an additional 16 shares during the period. MassMutual Private Wealth & Trust FSB boosted its position in IDEXX Laboratories by 4.4% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after purchasing an additional 16 shares during the period. Moss Adams Wealth Advisors LLC increased its holdings in IDEXX Laboratories by 3.3% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after purchasing an additional 17 shares in the last quarter. Finally, Stratos Wealth Partners LTD. raised its position in IDEXX Laboratories by 1.7% in the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock valued at $564,000 after purchasing an additional 18 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.2%

Shares of NASDAQ IDXX opened at $644.61 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The stock’s 50 day moving average price is $693.74 and its two-hundred day moving average price is $664.06. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The stock has a market capitalization of $51.47 billion, a P/E ratio of 49.32, a PEG ratio of 3.92 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on IDXX shares. Morgan Stanley increased their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $777.78.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.